AUS
NZ
UK
CA
USA
IND
Highlights:
- Share Price Rise: Shield Therapeutics PLC shares increased following the announcement of promising Phase III trial results for its iron deficiency treatment, Accrufer.
- Efficacy in Pediatrics: Accrufer demonstrated significant effectiveness in increasing hemoglobin levels in pediatric patients, paving the way for future regulatory approval submissions.
- Partnership and Market Potential: The company is set to receive a milestone payment from Norgine and aims to capitalize on the substantial demand for effective iron deficiency treatments in the U.S. market.
Shield Therapeutics PLC (LSE:STX) saw an 8% increase in its share price following the announcement of promising Phase III trial results for its iron deficiency treatment, Accrufer. This oral medication, scientifically known as ferric maltol, has shown significant potential for use in pediatric patients, specifically those aged 2 to 17.
The trial results revealed that Accrufer effectively increased hemoglobin levels, with an average rise of 1.25 g/dL over a 12-week period. Notably, the drug exhibited even higher efficacy in infants, marking a significant milestone in Shield's development program. This successful outcome sets the stage for the company to pursue regulatory approval for the use of Accrufer in children over the age of one month in both Europe and the United States, with plans to submit applications by mid-2025.
In addition to the trial results, Shield Therapeutics is poised to receive a €1 million milestone payment from its partner, Norgine, contingent on approval from the European Medicines Agency. This partnership underscores the collaborative efforts underway to enhance the accessibility of Accrufer to patients in need.
Market analysts, including those from Peel Hunt, have emphasized the pressing demand for effective treatments for iron deficiency, noting that approximately 20 million patients in the United States are affected by anemia. The firm highlighted that the success of Accrufer in capturing market traction will largely depend on the company’s ongoing commitment to marketing and commercializing the product.
Following the announcement, Shield's share price rose by 0.3p to 3.9p in early trading. The positive reception reflects the market's recognition of the trial's significance and the potential for Accrufer to fill a critical gap in the treatment landscape for pediatric iron deficiency.
As Shield Therapeutics moves forward, the focus will remain on obtaining the necessary regulatory approvals and effectively communicating the benefits of Accrufer to healthcare providers and patients. The completion of the Phase III trial and the subsequent plans for pediatric use mark a pivotal step in the company’s growth trajectory. With a strong emphasis on addressing unmet medical needs, Shield is well-positioned to enhance the lives of those suffering from iron deficiency anemia in children and potentially reshape the market landscape for iron supplementation therapies.
